OncoResponse, a US-based immunotherapy developer for cancer, has raised $40.6m in its series C round from a consortium including 3B Future Health Fund (Helsinn Investment Fund), the investment vehicle for cancer drug developer Helsinn Group.
Magnetar Group, Yonjin Venture and Bering Capital joined ther C round as new investors along with existing shareholders, RiverVest Venture Partners, Qatar Investment Authority (QIA), Redmile Group, Canaan Partners and Arch Venture Partners.
Ted Koutouzis, managing director at Magnetar Group, Daguang Wang from Yonjin Venture…
